DE3234947A1 - Arzneimittel zur behandlung von immundefektzustaenden - Google Patents
Arzneimittel zur behandlung von immundefektzustaendenInfo
- Publication number
- DE3234947A1 DE3234947A1 DE19823234947 DE3234947A DE3234947A1 DE 3234947 A1 DE3234947 A1 DE 3234947A1 DE 19823234947 DE19823234947 DE 19823234947 DE 3234947 A DE3234947 A DE 3234947A DE 3234947 A1 DE3234947 A1 DE 3234947A1
- Authority
- DE
- Germany
- Prior art keywords
- day
- fts
- eae
- treatment
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 10
- 208000016192 Demyelinating disease Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000001541 thymus gland Anatomy 0.000 claims description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 92
- LIFNDDBLJFPEAN-YTAPOSPOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-o Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-YTAPOSPOSA-N 0.000 description 59
- 108010003422 Circulating Thymic Factor Proteins 0.000 description 59
- 201000002491 encephalomyelitis Diseases 0.000 description 53
- 208000024891 symptom Diseases 0.000 description 32
- 241000700198 Cavia Species 0.000 description 27
- 241000282693 Cercopithecidae Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 18
- 206010033799 Paralysis Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 206010003591 Ataxia Diseases 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 5
- 230000007813 immunodeficiency Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000011694 lewis rat Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 206010010947 Coordination abnormal Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 241000195622 Astasia Species 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000015879 Cerebellar disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 108700016958 thymosin fraction 5 Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56148725A JPS5852225A (ja) | 1981-09-22 | 1981-09-22 | 脱髄疾患治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3234947A1 true DE3234947A1 (de) | 1983-04-07 |
Family
ID=15459209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823234947 Ceased DE3234947A1 (de) | 1981-09-22 | 1982-09-21 | Arzneimittel zur behandlung von immundefektzustaenden |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5112810A (enExample) |
| JP (1) | JPS5852225A (enExample) |
| DE (1) | DE3234947A1 (enExample) |
| FR (1) | FR2513125B1 (enExample) |
| GB (1) | GB2109684B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352665A (en) * | 1987-11-24 | 1994-10-04 | Mitsui Toatsu Chemicals, Incorporated | Method of treating disease caused by the infection of virus |
| JP2709839B2 (ja) * | 1987-12-25 | 1998-02-04 | 三井東圧化学株式会社 | 膵疾患等の予防・治療剤 |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| JPH01316328A (ja) * | 1988-06-15 | 1989-12-21 | Mitsui Toatsu Chem Inc | 老化防止、細胞賦活、老人病予防・治療のための薬剤 |
| US6150136A (en) * | 1995-11-14 | 2000-11-21 | The Regents Of The University Of California | Nucleotide sequence encoding oligodendrocyte-specific protein |
| US5756300A (en) * | 1995-11-14 | 1998-05-26 | Research Genetics, Inc. | Oligodendrocyte-specific protein and method for diagnosing and treating disease |
| FR2741076B1 (fr) * | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant |
| US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
| AU2001280199A1 (en) * | 2000-08-28 | 2002-03-13 | Akira Awaya | Medicinal compositions |
| US6716434B1 (en) * | 2000-09-19 | 2004-04-06 | Daniel R. Ansley | Composition and method for immunostimulation in non- mammalian vertebrates |
| US6719984B1 (en) * | 2000-09-19 | 2004-04-13 | Daniel R. Ansley | Composition and method for immunomodulation in mammals |
| US7858602B2 (en) * | 2000-10-16 | 2010-12-28 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| FR2830451B1 (fr) * | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| JP4721626B2 (ja) * | 2002-06-24 | 2011-07-13 | 昭 粟屋 | アレルギー性鼻炎・結膜炎あるいは皮膚アレルギーやアトピー性皮膚炎の予防・治療法 |
| US7695713B2 (en) * | 2002-08-08 | 2010-04-13 | Baylor College Of Medicine | Isolation and identification of T cells |
| PT2016414E (pt) * | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| ITRM20060584A1 (it) * | 2006-10-27 | 2008-04-28 | Francesco Bistoni | Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni |
| RU2010146489A (ru) | 2008-04-16 | 2012-05-27 | Момента Фармасьютикалз, Инк. (Us) | Анализ композиций сополимера аминокислот |
| FR2930156B1 (fr) | 2008-04-21 | 2011-10-28 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes. |
| MX2011009967A (es) * | 2009-03-26 | 2012-01-25 | Ford Henry Health System | Composiciones y metodo para mejorar el resultado neurologico despues de daño neural y enfermedad neurodegenerativa. |
| US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
| FR2962335B1 (fr) * | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| US11382885B2 (en) | 2017-06-07 | 2022-07-12 | The Regents Of The University Of California | Compositions for treating fungal and bacterial biofilms and methods of using the same |
| US12226386B2 (en) | 2018-12-03 | 2025-02-18 | The Regents Of The University Of California | Compositions and methods for treating biofilms |
| US12109176B1 (en) | 2023-04-20 | 2024-10-08 | Thomas Bryan | Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2512975A1 (de) * | 1974-03-25 | 1975-10-09 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
| DE2732587A1 (de) * | 1976-09-22 | 1978-03-23 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
| DE2822951A1 (de) * | 1977-05-25 | 1978-12-21 | Anvar | Neue polypeptide mit thymusaktivitaet oder antagonistischer aktivitaet und verfahren zu ihrer herstellung |
| DE2919218A1 (de) * | 1978-05-12 | 1979-11-22 | Takeda Chemical Industries Ltd | Nonapeptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2365347A2 (fr) * | 1976-09-22 | 1978-04-21 | Bach Jean Francois | Nouvelle hormone polypeptide possedant une activite thymique et son procede de preparation |
| JPS5839144B2 (ja) * | 1978-05-15 | 1983-08-27 | 株式会社トクヤマ | 炭酸モノエステルの製造方法 |
| JPS56148725A (en) * | 1980-04-18 | 1981-11-18 | Fujitsu Ltd | Magnetic head |
-
1981
- 1981-09-22 JP JP56148725A patent/JPS5852225A/ja active Granted
-
1982
- 1982-09-21 DE DE19823234947 patent/DE3234947A1/de not_active Ceased
- 1982-09-22 GB GB08227075A patent/GB2109684B/en not_active Expired
- 1982-09-22 FR FR8215984A patent/FR2513125B1/fr not_active Expired
-
1985
- 1985-05-15 US US06/734,259 patent/US5112810A/en not_active Expired - Fee Related
-
1990
- 1990-03-26 US US07/498,637 patent/US5464816A/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2512975A1 (de) * | 1974-03-25 | 1975-10-09 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
| DE2732587A1 (de) * | 1976-09-22 | 1978-03-23 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
| DE2822951A1 (de) * | 1977-05-25 | 1978-12-21 | Anvar | Neue polypeptide mit thymusaktivitaet oder antagonistischer aktivitaet und verfahren zu ihrer herstellung |
| DE2919218A1 (de) * | 1978-05-12 | 1979-11-22 | Takeda Chemical Industries Ltd | Nonapeptide |
Non-Patent Citations (2)
| Title |
|---|
| SIEGENTHALER, W. et.al.: Lehrbuch der inneren Medizin, Georg Thieme Verlag Stuttgart, New York 1984 (gutachtlich) * |
| Unlisted Drugs, Vol. 31, No. 4, 1979, S. 59, Chatham, New Jersey, US, Thymosin fr. 5 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5852225A (ja) | 1983-03-28 |
| GB2109684A (en) | 1983-06-08 |
| US5112810A (en) | 1992-05-12 |
| GB2109684B (en) | 1986-05-29 |
| FR2513125A1 (fr) | 1983-03-25 |
| JPH0371413B2 (enExample) | 1991-11-13 |
| US5464816A (en) | 1995-11-07 |
| FR2513125B1 (fr) | 1987-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3234947A1 (de) | Arzneimittel zur behandlung von immundefektzustaenden | |
| DE69636308T2 (de) | Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe | |
| DE69229975T2 (de) | Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten | |
| DE68905203T2 (de) | Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten. | |
| EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
| DE2911670A1 (de) | Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen | |
| DE1792410A1 (de) | Pharmakologische Komposition und Verfahren zu ihrer Herstellung | |
| CH672987A5 (enExample) | ||
| DE3526545A1 (de) | Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin | |
| DE60106026T2 (de) | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen | |
| DE3530767C2 (enExample) | ||
| DE3750235T2 (de) | Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen. | |
| EP0908176A1 (de) | Intravenöse Applikationsform von Thalidomid zur Therapie Immunologischer Erkrankungen | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE10157290A1 (de) | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III | |
| DE69021304T2 (de) | Vorbeugendes und therapeutisches Mittel gegen Hepatitis. | |
| EP0083925B1 (de) | Verfahren zur Behandlung der Azyklie bei Schafen oder Rindern | |
| DE69531166T2 (de) | Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen | |
| DE2660486C2 (de) | Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel | |
| DE3436638C2 (de) | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen | |
| DE2037942A1 (de) | Arzneimittel zur Verhinderung der Atheroklerose und des Wiederauftretens kardiocaskulärer Anfälle bei atherosklerotischen Säugetieren | |
| DE3239710C2 (de) | Peptid mit Nerven-regenerierenden Eigenschaften | |
| DE69124382T3 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
| EP1528922B1 (de) | Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose | |
| DE3784308T2 (de) | Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8128 | New person/name/address of the agent |
Representative=s name: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., |
|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D |
|
| 8125 | Change of the main classification |
Ipc: A61K 38/02 |
|
| 8131 | Rejection |